Inflammatory Markers in the Staging of Bipolar Disorder: A Systematic Review of the Literature

Merikangas, 2007, Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication, Arch Gen Psychiatry., 64, 543, 10.1001/archpsyc.64.5.543 Murray, 1997, Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study, Lancet., 349, 1436, 10.1016/S0140-6736(96)07495-8 Bourne, 2013, Neuropsychological testing of cognitive impairment in euthymic bipolar disorder: an individual patient data meta-analysis, Acta Psychiatr Scand., 128, 149, 10.1111/acps.12133 López-Jaramillo, 2010, Effects of recurrence on the cognitive performance of patients with bipolar I disorder: implications for relapse prevention and treatment adherence, Bipolar Disord., 12, 557, 10.1111/j.1399-5618.2010.00835.x Berk, 2011, Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors, Neurosci Biobehav Rev., 35, 804, 10.1016/j.neubiorev.2010.10.001 Post, 2012, Neurobiological correlates of illness progression in the recurrent affective disorders, J Psychiatr Res., 46, 561, 10.1016/j.jpsychires.2012.02.004 Kapczinski, 2008, Allostatic load in bipolar disorder: implications for pathophysiology and treatment, Neurosci Biobehav Rev., 32, 675, 10.1016/j.neubiorev.2007.10.005 Vieta, 2013, The clinical implications of cognitive impairment and allostatic load in bipolar disorder, Eur Psychiatry., 28, 21, 10.1016/j.eurpsy.2011.11.007 Fries, 2012, Staging and neuroprogression in bipolar disorder, Curr Psychiatry Rep., 14, 667, 10.1007/s11920-012-0319-2 Kupfer, 2015, Staging bipolar disorder: what data and what models are needed?, Lancet Psychiatry, 2, 564, 10.1016/S2215-0366(15)00096-6 Frey, 2013, Biomarkers in bipolar disorder: A positional paper from the International Society for Bipolar Disorders Biomarkers Task Force, Aust N Z J Psychiatry., 47, 321, 10.1177/0004867413478217 Berk, 2007, The potential utility of a staging model as a course specifier: a bipolar disorder perspective, J Affect Disord., 100, 279, 10.1016/j.jad.2007.03.007 Cosci, 2013, Staging of mental disorders: systematic review, Psychother Psychosom., 82, 20, 10.1159/000342243 Kapczinski, 2014, Staging systems in bipolar disorder: an International Society for Bipolar Disorders Task Force Report, Acta Psychiatr Scand., 130, 354, 10.1111/acps.12305 Kapczinski, 2009, The potential use of biomarkers as an adjunctive tool for staging bipolar disorder, Prog Neuropsychopharmacol Biol Psychiatry., 33, 1366, 10.1016/j.pnpbp.2009.07.027 Post, 2010, Mechanisms of illness progression in the recurrent affective disorders, Neurotox Res., 18, 256, 10.1007/s12640-010-9182-2 McGorry, 2010, Clinical staging: a heuristic and practical strategy for new research and better health and social outcomes for psychotic and related mood disorders, Can J Psychiatry., 55, 486, 10.1177/070674371005500803 Grande, 2014, Staging bipolar disorder: clinical, biochemical, and functional correlates, Acta Psychiatr Scand., 129, 437, 10.1111/acps.12268 Kauer-Sant’Anna, 2009, Brain-derived neurotrophic factor and inflammatory markers in patients with early- vs. late-stage bipolar disorder, Int J Neuropsychopharmacol., 12, 447, 10.1017/S1461145708009310 Barbosa, 2014, The immunology of bipolar disorder, Neuroimmunomodulation., 21, 117, 10.1159/000356539 Modabbernia, 2013, Cytokine alterations in bipolar disorder: a meta-analysis of 30 studies, Biol Psychiatry., 74, 15, 10.1016/j.biopsych.2013.01.007 Munkholm, 2013, Cytokines in bipolar disorder: A systematic review and meta-analysis, J Affect Disord., 144, 16, 10.1016/j.jad.2012.06.010 Reisberg, 1988, Functional assessment staging (FAST), Psychopharmacol Bull., 24, 653 Dickerson, 2013, Elevated C-reactive protein and cognitive deficits in individuals with bipolar disorder, J Affect Disord., 150, 456, 10.1016/j.jad.2013.04.039 Hope, 2013, Interleukin 1 receptor antagonist and soluble tumor necrosis factor receptor 1 are associated with general severity and psychotic symptoms in schizophrenia and bipolar disorder, Schizophr Res., 145, 36, 10.1016/j.schres.2012.12.023 Bai, 2014, Comparison of inflammatory cytokine levels among type I/type II and manic/hypomanic/euthymic/depressive states of bipolar disorder, J Affect Disord., 166, 187, 10.1016/j.jad.2014.05.009 Lotrich, 2014, The relationship between interleukin-1 receptor antagonist and cognitive function in older adults with bipolar disorder, Int J Geriatr Psychiatry., 29, 635, 10.1002/gps.4048 Barbosa, 2011, Increased plasma levels of soluble TNF receptor I in patients with bipolar disorder, Eur Arch Psychiatry Clin Neurosci., 261, 139, 10.1007/s00406-010-0116-z Barbosa, 2012, Executive dysfunction in euthymic bipolar disorder patients and its association with plasma biomarkers, J Affect Disord., 137, 151, 10.1016/j.jad.2011.12.034 Doganavsargil-Baysal, 2013, Levels of TNF-α, soluble TNF receptors (sTNFR1, sTNFR2), and cognition in bipolar disorder, Hum Psychopharmacol., 28, 160, 10.1002/hup.2301 Guloksuz, 2010, Cytokine levels in euthymic bipolar patients, J Affect Disord., 126, 458, 10.1016/j.jad.2010.04.027 Beato, 2007, Brazilian version of the Frontal Assessment Battery (FAB) Preliminary data on administration to healthy elderly, Dement Neuropsychol., 1, 59, 10.1590/S1980-57642008DN10100010 Randolph, 1998, The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity, J Clin Exp Neuropsychol., 20, 310, 10.1076/jcen.20.3.310.823 Gildengers, 2007, Cognitive functioning and instrumental activities of daily living in late-life bipolar disorder, Am J Geriatr Psychiatry., 15, 174, 10.1097/JGP.0b013e31802dd367 Fernandez-Botran, 1991, Soluble cytokine receptors: their role in immunoregulation, FASEB J, 5, 2567, 10.1096/fasebj.5.11.1868981 Kronfol, 2000, Cytokines and the brain: implications for clinical psychiatry, Am J Psychiatry., 157, 683, 10.1176/appi.ajp.157.5.683 Tsai, 2012, Inflammatory markers and their relationships with leptin and insulin from acute mania to full remission in bipolar disorder, J Affect Disord., 136, 110, 10.1016/j.jad.2011.08.022 Kim, 2007, Imbalance between pro-inflammatory and anti-inflammatory cytokines in bipolar disorder, J Affect Disord., 104, 91, 10.1016/j.jad.2007.02.018 Bonnín, 2012, Subthreshold symptoms in bipolar disorder: impact on neurocognition, quality of life and disability, J Affect Disord., 136, 650, 10.1016/j.jad.2011.10.012 Black, 2004, C-reactive protein, J Biol Chem., 279, 48487, 10.1074/jbc.R400025200 Lowe, 2005, Circulating inflammatory markers and risks of cardiovascular and non-cardiovascular disease, J Thromb Haemost., 3, 1618, 10.1111/j.1538-7836.2005.01416.x Sylvia, 2015, Medical burden in bipolar disorder: findings from the Clinical and Health Outcomes Initiative in Comparative Effectiveness for Bipolar Disorder study (Bipolar CHOICE), Bipolar Disord., 17, 212, 10.1111/bdi.12243 Corallini, 2008, TRAIL and osteoprotegerin: a role in endothelial physiopathology?, Front Biosci, 13, 135, 10.2741/2665 Bjerre, 2013, Osteoprotegerin (OPG) as a biomarker for diabetic cardiovascular complications, Springerplus., 2, 658, 10.1186/2193-1801-2-658 Montagnana, 2013, The role of osteoprotegerin in cardiovascular disease, Ann Med., 45, 254, 10.3109/07853890.2012.727019 Zhou, 2010, Conceptual and methodological issues relevant to cytokine and inflammatory marker measurements in clinical research, Curr Opin Clin Nutr Metab Care., 13, 541, 10.1097/MCO.0b013e32833cf3bc